ID: ALA189437

Max Phase: Preclinical

Molecular Formula: C25H26ClN5O3

Molecular Weight: 479.97

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccccc1N1CCN(CCn2c(=O)[nH]c3cc(-c4ccc(Cl)cc4)[nH]c3c2=O)CC1

Standard InChI:  InChI=1S/C25H26ClN5O3/c1-34-22-5-3-2-4-21(22)30-13-10-29(11-14-30)12-15-31-24(32)23-20(28-25(31)33)16-19(27-23)17-6-8-18(26)9-7-17/h2-9,16,27H,10-15H2,1H3,(H,28,33)

Standard InChI Key:  MOIUZUKSUMOMKZ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 479.97

Molecular Weight (Monoisotopic): 479.1724

AlogP: 3.17

#Rotatable Bonds: 6

Polar Surface Area: 86.36

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.65

CX Basic pKa: 6.78

CX LogP: 4.39

CX LogD: 4.30

Aromatic Rings: 4

Heavy Atoms: 34

QED Weighted: 0.44

Np Likeness Score: -1.31

References

1. Patanè E, Pittalà V, Guerrera F, Salerno L, Romeo G, Siracusa MA, Russo F, Manetti F, Botta M, Mereghetti I, Cagnotto A, Mennini T..  (2005)  Synthesis of 3-arylpiperazinylalkylpyrrolo[3,2-d]pyrimidine-2,4-dione derivatives as novel, potent, and selective alpha1-adrenoceptor ligands.,  48  (7): [PMID:15801833] [10.1021/jm040870h]

2. Pittalà V, Siracusa MA, Modica MN, Salerno L, Pedretti A, Vistoli G, Cagnotto A, Mennini T, Romeo G..  (2011)  Synthesis and molecular modeling of 1H-pyrrolopyrimidine-2,4-dione derivatives as ligands for the α1-adrenoceptors.,  19  (17): [PMID:21802308] [10.1016/j.bmc.2011.06.043]

Source

Source(1):

• Scientific Literature